(Q53665742)
Statements
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. (English)
1 reference
I F Tannock
1 reference
M J Moore
1 reference
D Osoba
1 reference
K Murphy
1 reference
A Armitage
1 reference
B Findlay
1 reference
C Coppin
1 reference
A Neville
1 reference
P Venner
1 reference
J Wilson
1 reference
1 April 1994
1 reference
12
1 reference
4
1 reference
689-694
1 reference
Identifiers
1 reference